Ameriprise
WHWK

Ameriprise’s Whitehawk Therapeutics WHWK Stock Holding History

Ameriprise’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-103,489
Closed -$209K – 3971
2023
Q4 		$209K Sell
103,489
-47,819
-32% -$201K ﹤0.01% 3716
2023
Q3 		$732K Buy
151,308
+329
+0.2% +$1.91K ﹤0.01% 3271
2023
Q2 		$1.03M Buy
150,979
+55,033
+57% +$428K ﹤0.01% 3159
2023
Q1 		$695K Buy
95,946
+37,171
+63% +$397K ﹤0.01% 3304
2022
Q4 		$754K Buy
+58,775
New +$767K ﹤0.01% 3255
2021
Q3 		– Sell
-3,796
Closed -$96K – 3981
2021
Q2 		$96K Sell
3,796
-1,410
-27% -$32.2K ﹤0.01% 3829
2021
Q1 		$101K Sell
5,206
-367
-7% -$8.45K ﹤0.01% 3774
2020
Q4 		$82K Sell
5,573
-7,568
-58% -$162K ﹤0.01% 3702
2020
Q3 		$296K Buy
+13,141
New +$277K ﹤0.01% 3428

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise's WHWK Position: Q1 2024 in Review

Ameriprise sold out of Whitehawk Therapeutics (WHWK) in Q1 2024, closing a stake of 103,489 shares — an estimated $209K sold.

Ameriprise first reported a position in WHWK in Q3 2020 and held it in 9 quarters. The position peaked at $1.03M in Q2 2023. 60 funds tracked by Wall St. Rank hold WHWK as of Q1 2024.

  • Ameriprise reported no remaining Whitehawk Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Ameriprise sold 103,489 Whitehawk Therapeutics shares in Q1 2024, an estimated $209K.
  • Ameriprise first reported a position in Whitehawk Therapeutics in Q3 2020 and held it in 9 quarters.
  • Ameriprise's Whitehawk Therapeutics position peaked at $1.03M in Q2 2023.
  • 60 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2024.

Based on Ameriprise's 13F filing for Q1 2024, filed 15 May 2024.